Content |
On 19th. Aug. Hyundai Pharm Inc., announced that it was designated as the new ATC which stands for Advanced Technology Center sponsored by the Ministry of Knowledge Economy in the Year 2012.
GPR119(G protein coupled receptor 119) agonist has dual effects, hypoglycemic efficacy and prevention of body weight gain. Hyundai pharm Inc., insisted its initial Lead compounds were evaluated to show differentiation in diabetes drug development area,
GPR119 stimulates the secretion of intestinal hormones such as GLP-1, which are distributed in intestinal L-cells, lowering blood glucose and promoting body weight reduction by appetite supression.
The ATC is a project backed by the Ministry of Knowledge Economy as part of efforts to support small and medium companies' R&D sector. It incites technological innovation and national competitiveness to conduct business.
Also, Hyundai Pharm Inc., made public that selected by Innovative Pharmaceutical company on 18th. Based on these, the company announced that it can be a starting point for a step forward to these opportunities through a brisk R & D activity.
|
|
24 
2/2 
